GNAQ mutations at codon 209 have been recently identified in approximately 50% of uveal melanomas (UM) and are reported to be oncogenic through activating the MAPK/Erk1/2 pathway. Protein kinase C (PKC) is a component of signaling from GNAQ to Erk1/2. Inhibition of PKC might regulate GNAQ mutation-induced Erk1/2 activation, resulting in growth inhibition of UM cells carrying GNAQ mutations. UM cells carrying wild type or mutant GNAQ were treated with the PKC inhibitor enzastaurin. Effects on proliferation, apoptosis, and signaling events were evaluated. Enzastaurin downregulated the expression of several PKC isoforms including PKCβII PKCθ, PKCε and/or their phosphorylation in GNAQ mutated cells. Downregulation of these PKC isoforms in GNAQ mutated cells by shRNA resulted in reduced viability. Enzastaurin exhibited greater antiproliferative effect on GNAQ mutant cells than wild type cells through induction of G1 arrest and apoptosis. Enzastaurin-induced G1 arrest was associated with inhibition of Erk1/2 phosphorylation, downregulation of cyclin D1, and accumulation of cyclin dependent kinase inhibitor p27Kip1. Furthermore, enzastaurin reduced the expression of antiapoptotic Bcl-2 and survivin in GNAQ mutant cells. Inhibition of Erk1/2 phosphorylation with a MEK specific inhibitor enhanced the sensitivity of GNAQ wild type cells to enzastaurin, accompanied by p27Kip1 accumulation and/or inhibition of enzastaurin-induced survivin and Bcl-2 upregulation. PKC inhibitors such as enzastaurin have activity against UM cells carrying GNAQ mutations through inhibition of the PKC/Erk1/2 pathway and induction of G1 arrest and apoptosis. Inhibition of the PKC pathway provides a basis for clinical investigation in patients with UM.
References
[1]
Singh AD, Borden EC (2005) Metastatic uveal melanoma. Ophthalmol Clin North Am 18: 143–150, ix.
[2]
Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, et al. (2008) Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 14: 951–956.
[3]
Triozzi PL, Eng C, Singh AD (2008) Targeted therapy for uveal melanoma. Cancer Treat Rev 34: 247–258.
[4]
Grover A, Alexander HR Jr (2004) The past decade of experience with isolated hepatic perfusion. Oncologist 9: 653–664.
[5]
Feldman ED, Pingpank JF, Alexander HR Jr (2004) Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 11: 290–297.
[6]
Onken MD, Worley LA, Long MD, Duan S, Council ML, et al. (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49: 5230–5234.
[7]
Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, et al. (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457: 599–602.
[8]
Hubbard KB, Hepler JR (2006) Cell signalling diversity of the Gqα family of heterotrimeric G proteins. Cell Signal 18: 135–50.
[9]
Ross EM, Wilkie TM (2000) GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 69: 795–827.
[10]
Martiny-Baron G, Fabbro D (2007) Classical PKC isoforms in cancer. Pharmacol Res 55: 477–486.
[11]
Engers R, Mrzyk S, Springer E, Fabbro D, Weissgerber G, et al. (2000) Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression. Br J Cancer 82: 1063–1069.
[12]
Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP (2001) Elevated protein kinase C ？II is an early promotive event in colon carcinogenesis. Cancer Res 61: 1375–1381.
[13]
Clark AS, West KA, Blumberg PM, Dennis PA (2003) Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance. Cancer Res 63: 780–786.
[14]
da Rocha AB, Mans DR, Regner A, Schwartsmann G (2002) Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 7: 17–33.
[15]
Koivunen J, Aaltonen V, Peltonen Juha (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett 235: 1–10.
[16]
Herbst RS, Oh Y, Wagle A, Lahn M (2007) Enzastaurin, a protein Kinase Cβ-Selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin Cancer Res 13: 4641s–4646s.
[17]
Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, et al. (2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ. Bioorg Med Chem Lett 13: 1857–1859.
[18]
Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, et al. (2005) The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65: 7462–7469.
[19]
Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, et al. (2004) LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53: 133–140.
[20]
Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, et al. (2006) Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 5: 1783–1789.
[21]
Hanauske A, Oberscchmidt O, Hanauske-Abel H, Lahn MM, Eismann U (2007) Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments. Invest New Drugs 25: 205–210.
[22]
Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, et al. (2007) Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor Enzastaurin (LY317615.HCl). Blood 109: 1669–1677.
[23]
Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, et al. (2007) Phase II study of enzastaurin, a protein kinase Cβ Inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25: 1741–1746.
[24]
Jane EP, Pollack IF (2008) The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Lett 268: 46–55.
[25]
Lee KW, Kim SG, Kim HP, Kwon E, You J, et al. (2008) Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 68: 1916–1926.
[26]
Folberg R, Kadrol SS, Frankel S, Valyi-Nagy K, Jager MJ, et al. (2008) Authenticating cell lines in ophthalmic research laboratories. Invest Ophthalmol Vis Sci 49: 4697–4701.
[27]
Populo H, Vinagre J, Lopes JM, Soares P (2011) Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol 95: 715–9.
[28]
Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2–4: 339–345.
[29]
Fields AP, Calcagno SR, Rishna M, Rak S, Leitges M, et al. (2009) Protein kinase Cβ is an effective target for chemoprevention of colon cancer. Cancer Res 69: 1643–1650.
[30]
Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501.
[31]
Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, et al. (2002) Mitogen activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8: 3728–3733.
[32]
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, et al. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756–759.
[33]
Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser D, et al. (2003) Lack of BRAF mutations in uveal melanoma. Cancer Res 63: 5712–5715.
[34]
Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, et al. (2005) Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 92: 2032–2038.
[35]
Morgillo F, Martinelli E, Troiani T, Laus G, Pepe S, et al. (2008) Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cβ inhibitor, in non-small cell lung cancer cells. Mol Cancer Ther 7: 1698–1707.
[36]
Rieger J, Lemke D, Maurer G, Weiler M, Frank B, et al. (2008) Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem 106: 2436–2448.
[37]
Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, et al. (2008) Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 99: 750–759.
[38]
Br？utigam K, Bauerschlag DO, Weigel MT, Biernath-Wüpping J, Bauknecht T, et al. (2009) Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation. Transl Oncol 2: 164–173.
[39]
Jane EP, Pollack IF (2010) Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signaling in malignant glioma cells. Eur J Cancer 46: 412–419.
[40]
Clark JA, Black AR, Leontieva OV, Frey MR, Pysz MA, et al. (2004) Involvement of the ERK signaling cascade in protein kinase C–mediated cell cycle arrest in intestinal epithelial cells. J Biol Chem 279: 9233–9247.
[41]
Greco S, Storelli C, Marsigliante S (2006) Protein kinaseC (PKC)-δ/ε mediate The PKC/Akt–dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. J Endocrinol 188: 79–89.
[42]
Guo K, Liu Y, Zhou H, Dai Z, Zhang J, et al. (2008) Involvement of protein kinase Cβ-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci 99: 486–496.
[43]
Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, et al. (2003) Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 278: 42409–42418.
[44]
Kili？ E, Brüggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, et al. (2004) The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res 14: 203–205.
[45]
Kortylewski M, Heinrich PC, Kauffmann ME, Bohm M, Mackiewicz A, et al. (2001) Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J 357: 297–303.
[46]
Philipp A, Schneider A, V？srik I, Finke K, Xiong Y, et al. (1999) Repression of cyclin D1: a novel function of MYC. Mol Cell Biol 14: 4032–4043.
[47]
Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, et al. (2009) Growth-inhibitory and anti-angiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11: 720–731.
[48]
Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, et al. (2006) Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci USA 103: 6332–6337.
[49]
Breitschopf K, Haendeler J, Malchow P, Zeiher AM, Dimmeler S (2000) Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol 20: 1886–1896.
[50]
Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, et al. (2001) Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108: 851–859.
[51]
Matsuoka H, Tsubaki M, Yamazoe Y, Ogaki M, Satou T, Itoh T, Kusunoki T, Nishida S (2009) Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res 315: 2022–32.
[52]
Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, Peschel C (2003) Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101: 278–85.
[53]
Retzer-Lidl M, Schmid RM, Schneider G (2007) Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer 121: 66–75.
